Frequently Asked Questions
The market is segmented based on , By Treatment (Antidepressants, Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Analgesics, Hormone Therapy, Exercise, Diet, Others), Diagnosis (Physical Examination, Others), Symptoms (Depression, Intense Anger, Mood Swings, Irritability, No interest in your usual activities, Anxiety, Trouble Concentrating, Appetite Changes, Feeling out of control, Fatigue, Cramps and Bloating, Tension, Headache, Insomnia, Joint or Muscle Pain, Breast Tenderness, Hot Flashes, Others), Dosage (Tablet, Injection, Others), Route of Administration (Oral, Intravenous, Others), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) – Industry Trends and Forecast to 2030.
.
The Global Premenstrual Dysphoric Disorder Market size was valued at USD 326.40 USD Million in 2022.
The Global Premenstrual Dysphoric Disorder Market is projected to grow at a CAGR of 3.7% during the forecast period of 2023 to 2030.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
